Elevated polyol pathway activity has been implicated in the development of diabetic complications, including neuropathy [1] . In diabetic models, inhibitors of the first enzyme in the pathway, aldose reductase, prevent or correct nerve conduction velocity (NCV) and regeneration deficits [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Clinical trials of aldose reductase inhibitors (ARIs) have shown modest improvements in neurological symptoms, NCV, sensory measures, and an increase in nerve fibre regeneration [14-17] despite a less effective polyol pathway blockade than was found necessary for functional effects in animal studies [6, 10, 18] .
reductase. These include the prevention of tissue sorbitol accumulation and sequelae consequent on the resultant osmotic imbalance such as reduced nerve myo-inositol [19, 20] , and deleterious effects on Na + -K + ATPase activity [21] . Aldose reductase requires NADPH as a co-factor, and depletion by elevated flux through the polyol pathway could alter the glutathione redox cycle, which would diminish protection against reactive oxygen species [22] . NADPH is also necessary for nitric oxide synthesis and the maintenance of vascular tone. These latter mechanisms have been linked to reduced nerve perfusion and oxygen supply [6, 10, [23] [24] [25] [26] which make major contributions to nerve dysfunction in diabetic patients and experimental models [27] [28] [29] . In contrast, other hypotheses consider the second half of the polyol pathway, conversion of sorbitol to fructose by sorbitol dehydrogenase, as the most important in the pathogenesis of diabetic complications including neuropathy. Fructose is a more effective glycating agent than glucose and advanced glycation end product (AGE) formation may contribute to diabetic complications [30] . Flux through the second part of the pathway also causes an increase in the NADH/NAD + ratio which has been hypothesised to cause a state of "hyperglycaemic pseudohypoxia" [31] which may contribute to neuropathy independent of changes in nerve perfusion [32, 33] .
Recently, specific sorbitol dehydrogenase inhibitors (SDIs) have become available [34] . Therefore, the aims of this study were to compare the biochemical effects of a pyrimidine-based SDI, WAY-135 706, with that of the ARI, WAY-121 509 [10, 11, 35] in tissues prone to diabetic complications, and to investigate the relative importance of the two enzymes of the polyol pathway for motor and sensory NCV and nerve blood flow abnormalities.
Materials and methods
The experiments were performed in accordance with regulations specified by the United Kingdom ' Animal Procedures Act, 1986' and the National Institutes of Health 'Principles of Laboratory Animal Care, 1985 revised version'.
Experimental groups and diabetes induction. Two studies were performed in which diabetes duration was 8 weeks and drug treatment was given over the final 2 weeks. Diabetes was induced by i. p. injection (40-45 mg ⋅ kg ) of streptozotocin (Sigma, St. Louis, Mo., USA or Zeneca, Macclesfield, UK) in mature 19-week-old male Sprague-Dawley rats obtained either from Charles River (Kingston, N. Y., USA) or from Aberdeen University breeding colony. Study 1, performed in Princeton, examined the levels of polyol pathway metabolites and myoinositol in lens, sciatic nerve, retina, renal cortex and medulla, and erythrocytes. Study 2, carried out in Aberdeen, was mainly concerned with measures of nerve function and vascular supply although nerve, aorta and diaphragm were also taken for polyol analysis.
In both studies the following groups were used: non-diabetic and diabetic controls, diabetic and non-diabetic rats treated with the SDI, WAY-135 706 (2-hydroxymethyl-4-(4-(N,Ndimethylaminosulfonyl-1-piperazino) pyrimidine), added to the food or the drinking water to yield a daily dose of approximately 250 mg ⋅ kg −1 , and diabetic rats treated with the ARI, WAY-121 509 [10, 11, 35] , added to the diet to yield a daily dose of approximately 10 mg ⋅ kg −1
. A pilot study examined the action of a lower SDI dose (100 mg ⋅ kg
) on sciatic motor NCV. Choice of the main SDI dose was based on this study, being increased to assess whether a greater NCV effect was possible.
For study 1 and 2, tissues were removed, frozen in liquid N 2 or solid CO 2 and stored at − 80°C before carbohydrate analysis. In study 1, kidneys were first perfused via the renal artery with sterile saline at 37°C to eliminate contamination by erythrocytes.
Tissue carbohydrates. Tissue glucose, sorbitol, fructose and myo-inositol concentrations were measured as their aldonitrile and cyclitol or alditol acetate derivatives as previously described [10, 11, 36] , using gas liquid chromatography and mass spectrometry detection. Protein content was estimated by the method of Peterson [37] .
Nerve conduction velocity. In final experiments for study 2, rats were anaesthetised with thiobutabarbitone (Zeneca) by i. p. injection (50-100 mg ⋅ kg
−1
). The trachea was cannulated for artificial ventilation and a carotid cannula was used to monitor mean systemic blood pressure. This surgery took approximately 10-15 min. Motor conduction velocity was measured between sciatic notch and knee for the nerve branch to tibialis anterior muscle as previously described [6] . In a subset of rats not used for blood flow determination, sensory NCV in saphenous nerve was also estimated [24] .
Nerve blood flow. Sciatic endoneurial blood flow was measured in the contralateral leg using microelectrode polarography and hydrogen clearance as previously described [6, 10, 38] . Briefly, rats were given neuromuscular blockade using dtubocurarine (Sigma, 2 mg ⋅ kg −1 via the carotid cannula) and were artificially ventilated (rate approximately 60 min
, ventilation volume approximately 2.5 ml). The level of anaesthesia was monitored by observing any reaction of blood pressure to manipulation, and supplementary thiobutabarbitone was given as necessary. Body core temperature was maintained at 37-38°C and nerve temperature was controlled within the range 35-37°C by radiant heat applied to a mineral oil pool that bathed the exposed sciatic nerve. A micromanipulator-mounted glass-insulated H 2 -sensitive platinum microelectrode was inserted into the middle portion of the nerve. 10 % H 2 was added to the inspired gas, the proportions of O 2 and N 2 being adjusted to 20 and 70 %, respectively. When the electrode H 2 current had stabilised, the H 2 supply was shut off and the clearance monitored. This was repeated at another nerve site more than 4 mm proximal or distal. Mono-or bi-exponential curves were fitted to the data by regression analysis (Prism; Graphpad, San Diego, Calif., USA) [39] . The fitting procedure gave r 2 values within the range 0.997-1.000 for all individual curves in this study. The slow exponent was taken to reflect nutritive capillary flow, and the fast exponent non-nutritive flow [27] . Composite (total) endoneurial flow was defined as the weighted sum of fast and slow components. The percentage of nutritive clearance was determined from the weighting coefficients for slow and fast components [10] . Vascular conductance was calculated by dividing blood flow by mean arterial blood pressure determined during the recording period. The average for the two clearance measurements was taken to represent sciatic endoneurial blood flow perfusion parameters.
One group of investigators has suggested that the reduced nerve blood flow in diabetic rats is a methodological artefact resulting from an inflammatory response in exposed nerves [32, 40] . Based on microsphere entrapment experiments, it was proposed that while blood flow in diabetic and non-diabetic nerves is initially equivalent, over a 2-h period, an inflammatory vasodilation, which is blunted in diabetic rats, produces a 2-3-fold blood flow increase in non-diabetic rats. This would result in an apparent relative decrease in nerve blood flow for diabetic rats. However, the application of the microsphere method to the measurement of nerve blood flow is questionable [24, 27, 28, 41] and other techniques that do not involve nerve exposure also show reduced nerve blood flow in diabetic rats [42] . Whether or not an operative procedure causes a significant inflammatory response depends critically on the degree of tissue trauma. Therefore, this point was examined in a pilot experiment where non-diabetic (n = 10) and 2-month diabetic (n = 8; plasma glucose 43.8 ± 1.6 mmol ⋅ l −1 ) rats were prepared for sciatic nerve blood flow measurement as described above but instead of hydrogen clearance measurements, flow changes were monitored using a laser-Doppler device (BPM 2 Laserflo; Vincent Medical, Slough, Bucks., UK), with a 0.8-mm diameter probe [43] . Readings were taken within 2 min of nerve exposure and at 2-min intervals for 140 min. A 51.9 ± 5.7 % reduction (p < 0.0001, Mann-Whitney U test) in laser-Doppler flux ( Fig. 1 ) was found within 2 min of nerve exposure in diabetic compared to non-diabetic rats and this deficit was maintained over the 140-min recording period, the average values being 22.0 ± 2.3 and 10.6 ± 0.8 laser-Doppler flux units in non-diabetic and diabetic groups, respectively (p < 0.0001). Mean systemic blood pressure during the recording period was lower in diabetic (115.7 ± 6.7 mm Hg) than non-diabetic (141.7 ± 2.5 mm Hg) rats (p < 0.0001). However, when this was taken into account by calculating vascular conductance, start and average values remained depressed (p < 0.0001) by diabetes (0.101 ± 0.015 and 0.092 ± 0.005 laserDoppler flux units ⋅ mm Hg −1 , respectively) compared to the non-diabetic group (0.167 ± 0.022 and 0.155 ± 0.016 laser-Doppler flux units ⋅ mm Hg −1 ). There was no indication of a systematic increase in laser-Doppler flux over the course of the experiments in non-diabetic or diabetic groups. For the former, this agrees with previously reported measurements over a 4-h period [44] . The deficit in laser-Doppler flux with diabetes also agrees with several reports [6, 8, 43, [45] [46] [47] [48] . It was further suggested that reduced blood flow in diabetic rats is only found when they are ketotic [49] . Measurements of plasma b -hydroxybutyrate using a standard test kit (Sigma), however, were not significantly different between diabetic and non-diabetic groups (4.9 ± 1.5 vs 2.1 ± 0.8 mg ⋅ dl −1 ). Thus, in this diabetic model and under the experimental conditions used in this laboratory, nerve blood flow measured by hydrogen clearance microelectrode polarography gives an assessment of endoneurial perfusion uncontaminated by putative artefacts due either to ketosis or to inflammatory reactions caused by excessive tissue damage.
Statistical analysis. Data were subjected to Bartlett's test for homogeneity of variance, and then to log transformation if necessary before one-way analysis of variance. Where overall significance (p < 0.05) was attained, individual between-group comparisons were made using the Student-Newman-Keuls range test to correct for multiple comparisons. When between-group variance differences could not be normalised by log transformation (body weights, plasma glucose, and some of the biochemical data), the Kruskal-Wallace non parametric analysis of variance was followed by Dunn's multiple comparison test.
Results
There was an approximate 5.4-fold increase in plasma glucose and 17.8 % decrease in body weight with diabetes, which were not significantly altered by SDI or ARI treatment (Table 1) .
Tissue carbohydrate levels from study 1 (nerve, lens, retina, kidney and erythrocytes) and study 2 (aorta and diaphragm) are shown in Table 2 . Glucose concentrations were elevated approximately 5-15 fold by diabetes, regardless of SDI or ARI treatment. Nerve sorbitol was increased 12-fold in untreated diabetic rats and this was matched in SDItreated non-diabetic rats. In the diabetic groups, ARI treatment suppressed sorbitol below the non-diabetic level whereas SDI treatment caused a 3.6-fold increase above levels found in untreated diabetic rats. Fructose concentration was increased 6.3-fold by diabetes. ARI treatment reduced fructose by 84 % below the non-diabetic value. SDI treatment caused similar marked reductions in non-diabetic (92 % vs non-diabetic control group) and diabetic (69 % vs non-diabetic control group) rats. Nerve myo-inositol content was 40 % decreased by diabetes and sorbitol accumulation in SDI-treated non-diabetic rats was also accompanied by a 26 % myo-inositol loss. ARI-treatment of diabetic rats caused a partial correction of myo-inositol content.
In SDI-treated diabetic rats there was a tendency for a further myo-inositol decrease below levels found in SDI-treated non-diabetic rats, although this was not statistically significant. Nerve water content, 1.401 ± 0.074 mg ⋅ mg dry weight −1 in the non-diabetic group, was increased to 1.751 ± 0.107 and 1.815 ± 0.108 mg ⋅ mg dry weight −1 in diabetic and SDI-treated diabetic groups, respectively (p < 0.05), whereas there was no significant increase in SDItreated non-diabetic (1.457 ± 0.098 mg ⋅ mg dry weight ) rats. Nerve polyol pathway metabolites were also measured in the Aberdeen colony rats used for NCV and blood flow determinations (Study 2). The results (data not shown) were in good agreement with those from the biochemical study above; a 13.5 ± 3.1-fold (p < 0.001) increase in sorbitol with diabetes was further increased 3.1 ± 0.3-fold (p < 0.001) with SDI treatment whereas ARI treatment suppressed sorbitol to 7.9 ± 0.1 % (p < 0.001) of the non-diabetic value. SDI treatment of non-diabetic rats caused a 19.2 ± 2.1-fold increase in nerve sorbitol to a value slightly higher (p < 0.05) than found with untreated diabetes. Fructose concentration, 4.2 ± 0.3-fold (p < 0.001) increased by diabetes, was reduced to below the non-diabetic level by both SDI (30.8 ± 2.3 %, p < 0.001) and ARI (13.4 ± 1.3 %, p < 0.001) treatment of diabetic rats and SDI treatment of non-diabetic rats (9.3 ± 1.2 %, p < 0.001). The plasma halflife of the SDI inhibitor is not known, although it has been suggested to be less than 1 h [33] . If that figure is accurate, then a waning of biochemical effects could have occurred during the time required to make the functional measurements. To examine this possibility, nerve fructose concentrations were compared in rats used only for NCV (∼ 30 min) or blood flow (∼ 2-3 h) measurements. Fructose remained reduced below the non-diabetic and diabetic levels by 71.3 ± 5.8 % and 93.1 ± 1.4 %, respectively for SDItreated diabetic rats (n = 6) used only for NCV, and by 67.9 ± 1.6 % and 92.3 ± 0.4 % for SDI-treated diabetic rats (n = 10) used for blood flow measurements. For SDI-treated non-diabetic rats, fructose was 88.7 ± 2.9 % depressed in the NCV only subgroup (n = 6) and 92.0 ± 0.9 % in the blood flow subgroup (n = 10). Thus, the SDI was effective with no evidence of a decline in the degree of inhibition during functional measurements.
Although absolute levels of carbohydrates varied considerably between tissues, the patterns of ARI and SDI effects on sorbitol in lens, retina, renal cortex and medulla, erythrocytes, aorta and diaphragm (Table 2) were similar to that for nerve. Elevated sorbitol in diabetes was prevented by ARI whereas it was exacerbated by SDI treatment. In non-diabetic rats, SDI treatment caused sorbitol levels to roughly match those of untreated diabetes. In contrast both ARI and SDI treatments suppressed lens, retina and erythrocyte fructose concentrations. In aorta, fructose suppression by the SDI was only partial, and was not statistically significant for ARI treatment. For diaphragm, fructose levels were not increased by diabetes or markedly altered by the inhibitors. Renal cortex and medulla fructose concentrations were elevated by diabetes but only modestly reduced by ARI or SDI treatment. In non-diabetic rats, SDI treatment did not significantly reduce fructose levels in renal tissues, and caused only a modest reduction in diaphragm. However, fructose was markedly reduced by the SDI in lens, retina, erythrocytes and aorta.
Myo-inositol changes varied between tissues and with diabetes and treatment. In lens, as in nerve, myo-inositol was reduced by diabetes and partially corrected by ARI treatment. SDI treatment of nondiabetic rats depressed lens myo-inositol content. In retina, diabetes and ARI treatment had no effect on myo-inositol concentrations; however, SDI treatment reduced retinal myo-inositol in both diabetic and non-diabetic rats. Diabetes had no effect on myoinositol levels in renal medulla, erythrocytes or aorta. Renal cortex myo-inositol was depressed by diabetes and unaffected by ARI or SDI treatments. Conversely, in diaphragm, myo-inositol was markedly elevated by diabetes, but ARI and SDI treatments had no effect. Myo-inositol and sorbitol content were inversely correlated when data from untreated and treated diabetic groups were pooled for nerve (r 2 = 0.498, p < 0.0001) and lens (r 2 = 0.786, p < 0.0001) but no significant correlation was found for retina, erythrocytes, renal cortex and medulla, aorta or diaphragm.
Sciatic motor NCV (Fig. 2 ) was 20.2 ± 0.7 % reduced (p < 0.001) by 8 weeks of diabetes. ARI treatment with WAY-121 509 for the last 2 weeks , significantly reduced compared to non-diabetic (p < 0.001) and ARI-treated diabetic (p < 0.001) groups. A similar outcome was apparent for saphenous sensory NCV (Fig. 3) ; the 13.9 ± 0.7 % deficit with diabetes (p < 0.001) was completely corrected by ARI treatment (p < 0.001) while remaining totally resistant to the high SDI dose.
There was a 48.6 ± 2.9 % reduction (p < 0.001) in sciatic nutritive (capillary) endoneurial blood flow (Fig. 4 A) with diabetes which was 77.9 ± 7.8 % corrected by ARI treatment although a small (10.8 ± 3.8 %) but significant (p < 0.05) deficit remained. SDI treatment of diabetic rats did not significantly alter blood flow, which remained in the lower half of the diabetic range, significantly reduced compared to non-diabetic (p < 0.001) or ARI-treated diabetic (p < 0.001) groups. For SDI-treated non-diabetic rats, blood flow was slightly (15.5 ± 3.8 %, p < 0.01) reduced compared to the non-diabetic group. There were between-group variations in mean systemic blood pressure (Fig. 4 B) recorded during the hydrogen clearance measurements, with significant reductions in diabetic and ARI-treated diabetic groups compared to non-diabetic rats (p < 0.05). Differences in perfusion pressure may have contributed to the flow changes with diabetes and treatment as vasa nervorum has a minimal capacity for pressure autoregulation [27] . When this is taken into account by expressing the data as endoneurial nutritive vascular conductance (Fig. 4 C) , the small deficits apparent from the blood flow data in ARI-treated diabetic and SDI-treated non-diabetic rats disappeared compared to the nondiabetic group. However, vascular conductance in the untreated diabetic group was 41.2 ± 3.6 % reduced (p < 0.001) and a 49.8 ± 2.6 % deficit (p < 0.001) persisted with SDI-treated diabetes; for both of these groups, vascular conductance was also significantly depressed (p < 0.001) compared to the ARI-treated diabetic group.
The hydrogen clearance technique also allows the measurement of total endoneurial perfusion, a composite of nutritive, large vessel and arteriovenous shunt flows [27] . Composite flow (Fig. 5 A) and conductance (Fig. 5 B) were decreased by diabetes to the extent of 56.5 ± 4.7 % (p < 0.001) and 49.0 ± 6.2 % (p < 0.001), respectively. This was not significantly altered by ARI or SDI treatment, values remaining reduced (p < 0.001) compared to the non-diabetic group. In addition, for the SDI-treated non-diabetic group, composite flow and conductance were diminished by 31.6 ± 9.1 % (p < 0.01) and 24.9 ± 10.0 % (p < 0.05), respectively compared to non-diabetic rats, although these measures remained significantly greater (p < 0.05) than for untreated diabetes.
Discussion
The data show that the SDI, WAY-135 706, had a pronounced biochemical effect in several tissues. Sorbitol elevation was greater than noted in other SDI studies for nerve, lens and erythrocytes [33, 34] . An earlier study reported 8.7 and 1.4-fold increases in nerve and erythrocytes of non-diabetic rats treated with 100 mg ⋅ kg −1 of SDI157 (the pro-drug for WAY-135 706) and a 2.9-fold elevation in lens for 50 mg ⋅ kg −1 [34] . This compares with 11.5, 6.4 and 17.4-fold changes, respectively, noted in our study. A second report [33] showed 2-4-fold sorbitol increases with S-0773 (equivalent to SDI157) in ocular tissues, sciatic nerve and blood of diabetic rats using doses of 50-150 mg ⋅ kg
. Fructose has been examined in less detail; 150 mg ⋅ kg −1 S-0773 reduced diabetic levels by 50, 70 and 50 % for retina, nerve and lens, respectively [33] . Inhibition in our study was higher, 90, 95 and 93 %, respectively, and comparable to that for ARI treatment. This is important for potential effects on nerve function because a very high polyol pathway blockade is necessary to correct NCV deficits in diabetic rats [6, 11, 18] .
Elevated kidney fructose levels were barely altered by both the SDI and ARI, suggesting that much of the increase in diabetes comes from a source other than the polyol pathway. The ARI, ponalrestat, only partially decreased kidney fructose in diabetic rats [50] , and in isolated glomeruli exposed to a high glucose concentration, tolrestat suppressed sorbitol production without affecting fructose levels [51] . Deleterious changes in renal structure and function have been attributed to increased AGE formation in diabetes [52] . If fructosylation is an important source of AGEs [30] , then the data suggest that SDI treatment would be ineffective in protecting against these renal changes. For diaphragm, diabetes did not increase fructose, suggesting low sorbitol dehydrogenase activity or high fructose permeability. The fructose lowering in SDI-treated non-diabetic rats and a 6-fold sorbitol elevation for SDI-treated diabetes suggest a combination of these factors. Thus, SDI-induced fructose reductions are tissue dependent, probably reflecting a heterogeneity of fructose sources and differing activities of the two polyol pathway enzymes.
A partial reciprocity between sorbitol and myoinositol levels was noted for nerve and lens, in accordance with a role as a compensatory osmolyte [20, 53] . This may be reflected by changes in nerve water content. Thus, osmolyte levels (sorbitol, fructose and myo-inositol) were approximately 65 nmol ⋅ mg protein −1 in nerves from non-diabetic rats compared to 145 and 157 nmol ⋅ mg protein −1 in diabetic and SDItreated diabetic groups. For SDI-treated non-diabetic and ARI-treated diabetic rats, water content was unchanged and osmolyte levels were 72 and 37 nmol ⋅ mg protein −1 , respectively. NCV was unaffected in SDI-treated non-diabetic rats although nerve sorbitol levels were similar to those found in untreated diabetes. In SDI-treated diabetic rats, nerve polyol accumulation approached that of galactosaemic rats which have marked NCV deficits [1, 54] . There was no worsening of NCV by these added potential osmotic insults, which provides further evidence against the involvement of osmotic disruption in the aetiology of NCV deficits [1, 19, 55] . This agrees with the conclusions from ARI dose-response studies, where NCV correlated poorly with polyol levels, but showed a strong relationship to changes in nerve blood flow [6, 11] .
In renal medulla, sorbitol production has a role in cell-volume regulation [55] . However, medulla myoinositol was not affected by diabetes, SDI or ARI treatment, implying that it has no osmotic function. A 23 % diabetic myo-inositol deficit in renal cortex was unaffected by ARI or SDI treatment, indicating dissociation from polyol pathway effects. While ARI and myo-inositol treatments partially protect against early increases in glomerular filtration and albumin excretion in diabetic rats [56, 57] , myo-inositol does not prevent chronic renal changes [58] . Myo-inositol was unaltered by diabetes in retina and aorta, implying that it is not a major factor in the complications of these tissues. Diabetes increased diaphragm myoinositol levels, in agreement with other findings for striated muscle [59, 60] . This was unaffected by ARI and SDI treatment, indicating a minimal role in polyol pathway-related myopathy [61] .
SDI treatment had no effect on diabetic motor or sensory NCV deficits despite a very high suppression of sciatic nerve fructose production by the second half of the polyol pathway. In contrast, ARI treatment, which reduced flux through both halves of the polyol pathway, almost completely restored nerve function. Thus, the first polyol pathway reaction must make the major contribution to experimental diabetic neuropathy. In galactose-fed rats, galactose is converted to galactitol by aldose reductase, however, unlike sorbitol, galactitol is not further metabolised by sorbitol dehydrogenase [1] . In this model, stimulation of the aldose reductase step leads to ARI-preventable changes in nerve function and morphology resembling those of diabetes [54, [62] [63] [64] [65] . The importance of aldose reductase is also emphasised by the exacerbated NCV deficits seen in diabetic and galactosaemic mice transgenic for human aldose reductase [66] .
Time-course considerations influenced the experimental design; NCV in our model was corrected in 7-11 days by the ARIs, ZD5522 [6] and WAY-121 509 (Dines, Cameron and Cotter, unpublished observations). Biochemical changes in rat nerves in vivo occur within a few hours of treatment with pyrimidine-based SDIs and ARIs [1, 34] . Thus, an agent that does not correct NCV deficits over the same period as ARIs cannot be acting via mechanisms dependent on the immediate consequences of polyol pathway flux (sorbitol and fructose accumulation and changes in NADPH/NADP + and NADH/NAD + ratios). The putative redox change in pseudohypoxia [31] , an increased NADH/NAD + ratio, falls into this category, therefore, the NCV data for SDI treatment suggest that this hypothesis does not apply to nerve.
A long-term study on caudal NCV showed no effect of SDI157 (100 mg ⋅ kg ) over 43-221 days, although a small improvement was alleged at 15 days [34] . Another caudal nerve investigation claimed a modest effect of S-0773 (100-150 mg ⋅ kg − 1 ) over 4 weeks [33] ; however, neither analysis took account of multiple comparisons to protect against type 1 errors; statistical significance disappears when Bonferroni or Student-Newman-Keuls corrections are applied. Caudal nerve studies also make conflicting and statistically dubious claims of increased [34] or decreased [33] NCV in SDI-treated non-diabetic rats. The average trend is in accord with this study which found no NCV effects of the SDI in non-diabetic rats.
A recent brief report claimed that 14 weeks of SDI treatment (200 mg ⋅ kg −1 CP166 572, equivalent to WAY-135 706), caused an 82 % reduction of nerve fructose and prevented tibial-interosseous motor NCV deficits in diabetic rats [67] . This is at variance with the caudal nerve results [33] , and contrasts with the sciatic and saphenous nerve data despite 95 % inhibition of fructose accumulation; the reason for the discrepancy is unclear. It is unlikely to depend on the use of a reversal rather than a prevention paradigm in this study; NCV is rapidly corrected by a variety of interventions in the nerve branches examined [28] . An alternative explanation is that while shortterm NCV effects depend on the first half of the polyol pathway, long-term effects might depend on prevention of fructosylation and AGE accumulation [30] in nerve and vasa nervorum. In this respect, while SDIs could reduce AGE formation, reversal treatment would be less effective as the AGEs initially formed during the untreated diabetic period would continue their deleterious free-radical producing reactions. However, in contrast to this explanation, aminoguanidine, which prevents AGE formation, rapidly corrects established NCV deficits within 10 days of treatment [68] . Thus, a long-term SDI action in the absence of short-term effects suggests drug-specific actions unrelated to the polyol pathway. Further NCV studies using structurally dissimilar SDIs are needed to clarify this point. It could also be argued that myo-inositol changes, uncorrected by SDI treatment of diabetic rats [33, 67] , are critical for NCV. However, vasodilators, essential fatty acids and antioxidants correct NCV despite reduced myoinositol levels, and myo-inositol treatment does not alter NCV in our model [6, 10, 28, 43] .
While the ARI corrected impaired sciatic endoneurial nutritive blood flow in diabetic rats, the SDI was without effect. The diabetic deficit and the effect of ARI treatment are consistent with a large number of reports [6, 8-11, 27, 28, 42, 45-48] . ARIs normalise nutritive perfusion primarily by diverting arteriovenous shunt flow to the capillary bed [6, 10, 11] . This probably results from improved protection against oxidative stress by the glutathione redox cycle, which like the first but not the second reaction of the polyol pathway, is NADPH-dependent [6, 10, 11, 28] . Similar blood flow and NCV changes were found for treatment with the antioxidant and glutathione substrate, N-acetyl-L-cysteine [69] . Thus, ARI treatment has little effect on total endoneurial flow. There is a good correlation between NCV and nutritive flow (but not total endoneurial flow) in diabetic rats when data from several therapeutic intervention studies are pooled [70] ; therefore, a lack of action on nutritive perfusion probably underlies the poor SDI effect on NCV. An earlier study attempted to estimate nerve perfusion using microsphere entrapment, the results being interpreted as an increase in flow with diabetes which was partially prevented by SDI treatment [33] . Data obtained by the microsphere method, however, do not agree with other invasive and non-invasive techniques for flow assessment in nerve, therefore it is of questionable validity [27, 28, 41] . Nonetheless, reduced microsphere entrapment by SDI treatment in diabetic rats indicates a vascular effect, albeit not directly related to nutritive blood flow. Platelet aggregation, thrombus formation and leucocyte-endothelium interactions are increased in diabetes [71, 72] . It is possible that SDI treatment might decrease one or more of these factors, which could explain reduced microsphere trapping and suggests a direction for future research. SDI treatment of non-diabetic rats reduced total endoneurial perfusion, although this did not impinge on nutritive flow or NCV [10] . The mechanism is unclear; SDIs accelerate cataract formation and depress lens glutathione levels while ARIs have the opposite effect [34] . If SDIs also reduce vasa nervorum glutathione, impaired antioxidant activity would alter blood flow, as noted in pro-oxidant-treated non-diabetic rats [23] .
In conclusion, ARIs have beneficial actions on nerve perfusion and conduction in experimental diabetes, whereas SDIs lack these effects. Thus, the conversion of glucose to sorbitol via aldose reductase is the crucial polyol pathway step in rats, contributing to diabetic neuropathy by reducing endoneurial capillary perfusion. SDI-induced sorbitol accumulation may exacerbate the pathogenesis of some diabetic complications such as cataracts, and a tendency towards impaired total nerve perfusion suggests that while SDIs are a valuable research tool they would be unsuitable for therapeutic intervention.
